Ignite Creation Date:
2025-12-24 @ 1:57 PM
Ignite Modification Date:
2026-02-21 @ 1:36 AM
Study NCT ID:
NCT01850095
Status:
UNKNOWN
Last Update Posted:
2013-05-09
First Post:
2013-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Influence of Peripheral Androgen Conversion at Women Adult Acne
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000152', 'term': 'Acne Vulgaris'}], 'ancestors': [{'id': 'D017486', 'term': 'Acneiform Eruptions'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012625', 'term': 'Sebaceous Gland Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C010038', 'term': 'azelaic acid'}, {'id': 'C534342', 'term': 'drospirenone and ethinyl estradiol combination'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 60}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2012-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-05', 'completionDateStruct': {'date': '2015-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2013-05-08', 'studyFirstSubmitDate': '2013-05-01', 'studyFirstSubmitQcDate': '2013-05-08', 'lastUpdatePostDateStruct': {'date': '2013-05-09', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-05-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Application of the questionnaire index of quality of life in Acne', 'timeFrame': '6 months', 'description': 'AcneQol (Girman et al, 1996, Martin et al, 2001, Fehnel et al, 2003),'}, {'measure': 'Immunohistochemical analysis with quantitative digital blind:', 'timeFrame': '6 months', 'description': 'For immunohistochemistry will be used the following markers:\n\n* a polyclonal rabbit anti-TLR2 (ABBIOTEC 251,110) Biogen, Brazil.\n* mouse monoclonal anti-CD1d, clone NOR3.2 (Genway 20-272-1903). Biogen, Brazil.\n\nStatistical comparisons are made between the following groups: control group 2 and the region with inflammatory lesions in the treatment group, region and region inflammatory non-inflammatory group of medications and treatment before inflammatory region before and after treatment.'}, {'measure': 'Serological blood measurements', 'timeFrame': '6 months', 'description': 'Comparison of serological blood measurements of free and total testosterone, dihydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and androsterone glucuronide, before and after the treatment.'}], 'primaryOutcomes': [{'measure': 'Clinical evaluation of the treatment group', 'timeFrame': '6 months', 'description': 'by the researcher: by counting the inflammatory lesions. by the research subjects: the general appearance of skin at the time of study entry and after the treatment. Will be used a 4-point scale: 0 = no acne, 1 = mild acne, moderate acne, and 2 = 4 = severe acne.'}], 'secondaryOutcomes': [{'measure': 'Photographic study of the treatment group', 'timeFrame': '6 months', 'description': 'This evaluation will be performed by two independent dermatologists, the degree of change in the intensity of acne, comparing the pre and post treatment photos through a 5-point scale: -2 = much worse, -1 = worse, 0 = unchanged; +1 = better, +2 = much better.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['acne', 'adult', 'women', 'TLR', 'CD1d', 'androgens'], 'conditions': ['Acne', 'Quality of Life']}, 'referencesModule': {'references': [{'pmid': '19588637', 'type': 'BACKGROUND', 'citation': 'Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol. 2009 Jul;8(7):615-8.'}, {'pmid': '21710106', 'type': 'BACKGROUND', 'citation': 'Shen Y, Wang T, Zhou C, Wang X, Ding X, Tian S, Liu Y, Peng G, Xue S, Zhou J, Wang R, Meng X, Pei G, Bai Y, Liu Q, Li H, Zhang J. Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities. Acta Derm Venereol. 2012 Jan;92(1):40-4. doi: 10.2340/00015555-1164.'}, {'pmid': '12833004', 'type': 'BACKGROUND', 'citation': 'Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37. doi: 10.1067/mjd.2003.618. No abstract available.'}, {'pmid': '15556729', 'type': 'BACKGROUND', 'citation': 'Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004 Sep-Oct;22(5):419-28. doi: 10.1016/j.clindermatol.2004.03.010.'}, {'pmid': '19555434', 'type': 'BACKGROUND', 'citation': 'Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R, Schagen S, Tsatsou F, Zouboulis CC. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009 Oct;18(10):821-32. doi: 10.1111/j.1600-0625.2009.00890.x. Epub 2009 Jun 23.'}, {'pmid': '9703121', 'type': 'BACKGROUND', 'citation': 'White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S34-7. doi: 10.1016/s0190-9622(98)70442-6.'}, {'pmid': '10495379', 'type': 'BACKGROUND', 'citation': 'Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999 Oct;41(4):577-80.'}, {'pmid': '9039297', 'type': 'BACKGROUND', 'citation': 'Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol. 1997 Jan;136(1):66-70.'}, {'pmid': '11843213', 'type': 'BACKGROUND', 'citation': 'Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol. 2001 Nov;15(6):541-5. doi: 10.1046/j.1468-3083.2001.00357.x.'}]}, 'descriptionModule': {'briefSummary': 'Acne vulgaris is a chronic inflammatory disease that affects the pilosebaceous unit. Recent studies have demonstrated an increase number of acne cases in adult women. These cases are predominantly normoandrogenic and have some clinical differences when compared with the most common group, the adolescent. The local glandular metabolism converts some hormonal precursors to more active substances that increase the sebum production, leaving these areas more prone to increase the colonization to Propionibacterium Acnes (P. Acnes). Toll-like receptor 2, expressed by inflammatory cells play a crucial role in the innate immune response to this bacterium. Previous studies confirm that exist a reduced expression of CD1d by keratinocytes in acne lesion, what can be interpreted as a low antigen-present function. The influence of hormonal alteration in the sebaceous glands could modulate the expressions of TLR-2 and CD1d explaining the persistence of lesions in adult women. The change to more estrogenic metabolism, with use of specific contraceptive pills could normalize this immune-mediated inflammatory process.\n\nObjective\n\nTo analyze how the peripheral androgen conversion can influence the toll-like receptor 2 and CD1d expression in women with inflammatory acne before and after 6 months of oral contraceptives with anti-androgen activity.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '44 Years', 'minimumAge': '26 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\nTo all:\n\n1. Signing the consent form before any study procedures;\n2. women aged 26 to 44 years, not pregnant and in good health;\n3. no topical treatment for acne in the past three months,\n4. absence of the use of oral antibiotics in the last 3 months;\n5. absence of the use of isotretinoin in the last 2 years;\n6. absence of oral contraceptive use in the last 3 months;\n7. absence of clinical evidence of immunosuppression and\n8. accordance with the conditions of study, ability to understand and strictly follow the instructions given.\n\nFor the oral contraceptives group:\n\n1. No contraindications to the use hormonal contraceptives.\n\nFor the azelaic acid group:\n\n1. Absence of hypersensitivity to azelaic acid.\n\nExclusion Criteria:\n\nFor all\n\n1. Women who do not agree with the conditions of the study or without the ability to understand and closely follow the guidelines received without availability to attend the revaluations or who refuse to sign the Informed Consent Form;\n2. pregnant or lactating women;\n3. use of the following oral medications: cortisone derivatives, lithium, anticonvulsants, isoniazid, oral contraceptives, androgens, danazol, iodides, bromides, disulfiram, cyclosporine, azathioprine, thiuram, vitamins B2, B6 and B12;\n4. treatment of facial skin with topical retinoids (tretinoin and adapalene), azelaic acid, benzoyl peroxide, clindamycin, erythromycin, nicotinamina, alone or in combination, in the past 3 months;\n5. treatment with oral antibiotics in the past 3 months;\n6. acnogenics cosmetics.\n\nFor the group treated with oral contraceptives:\n\n1\\. Presence of contraindications to oral contraceptive use:\n\n1. Smokers over 35 years;\n2. history of deep venous thrombosis;\n3. history of stroke;\n4. history of breast cancer;\n5. presence of jaundice, and severe active liver disease or biliary disease;\n6. diabetes mellitus for more than 20 years or eye injury, or neurological impairment;\n7. blood pressure greater than or equal to 160 to 100 for systolic and diastolic;\n8. cardiovascular disease and\n9. presence of severe headache associated with blurred vision frequently.\n\nFor the group treated with azelaic acid:\n\n1.Presense of allergic and / or irritating symptoms to the use of azelaic acid.\n\nFor the control group 1:\n\n1\\. History, clinical signs and / or laboratory evidence of hyperandrogenism. 2 .Presence of inflammatory acne.\n\n\\-'}, 'identificationModule': {'nctId': 'NCT01850095', 'briefTitle': 'The Influence of Peripheral Androgen Conversion at Women Adult Acne', 'organization': {'class': 'OTHER', 'fullName': 'Federal University of São Paulo'}, 'officialTitle': 'The Influence of Peripheral Androgen Conversion at Toll-like Receptors-2 and CD1d Expressions in Human Keratinocytes as Well as Their Modulation After 6 Months Treatment With Oral Contraceptive.', 'orgStudyIdInfo': {'id': '1622/11'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'treatment 1', 'description': 'topical acid azelaic, used 2 times a day for 6 months', 'interventionNames': ['Drug: treatment azelaic acid (azelan)']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'treatment 2', 'description': 'contraceptive with drospirenone/ethinyl estradiol used for 6 months', 'interventionNames': ['Drug: dorspirenone/ethynil estradiol']}, {'type': 'NO_INTERVENTION', 'label': 'control', 'description': 'control group ( only take biopsies and blood samples )'}], 'interventions': [{'name': 'treatment azelaic acid (azelan)', 'type': 'DRUG', 'otherNames': ['azelaic acid (azelan)'], 'description': 'treatment for 6 months', 'armGroupLabels': ['treatment 1']}, {'name': 'dorspirenone/ethynil estradiol', 'type': 'DRUG', 'otherNames': ['(yaz)'], 'armGroupLabels': ['treatment 2']}]}, 'contactsLocationsModule': {'locations': [{'zip': '04038-001', 'city': 'São Paulo', 'state': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'marco rocha, md', 'role': 'CONTACT', 'email': 'marcoderm@hotmail.com', 'phone': '55-11-55799331'}, {'name': 'marco rocha, md', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'edileia bagatin, Phd', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Federal University of São Paulo-Dermatology', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}], 'centralContacts': [{'name': 'marco rocha, md', 'role': 'CONTACT', 'email': 'marcoderm@hotmail.com', 'phone': '55-11-55799331'}], 'overallOfficials': [{'name': 'marco rocha, md', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'UNIFESP-EPM'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Marco Alexandre Dias da Rocha', 'class': 'OTHER'}, 'collaborators': [{'name': 'Fleury', 'class': 'UNKNOWN'}, {'name': 'Associacao Fundo de Incentivo a Psicofarmcologia', 'class': 'OTHER'}, {'name': 'Bayer', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'MD', 'investigatorFullName': 'Marco Alexandre Dias da Rocha', 'investigatorAffiliation': 'Federal University of São Paulo'}}}}